tradmap

SLXN Earnings Silexion Therapeutics Corp

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
$0 $197 $395 2023 2024 2025
EPS
Net income (annual)
-$17M -$8M $0 2023 2024 2025
Net income
Return on equity (annual)
-458% -22% 414% 0% 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
$0 $377 $755 Q2 '23 Q3 '23 Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26
EPS
Net income (quarterly)
-$12M -$6M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-8070% -3906% 259% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–13 of 13
Q2 20262026-06-3012.412026-08-1410-Q
Q1 20262026-03-310.852026-05-1510-Q
FY 20252025-12-318.962026-03-1710-K
Q3 20252025-09-3010.362025-11-1210-Q
Q2 20262025-06-3082.122026-08-1410-Q
Q1 20262025-03-313.842026-05-1510-Q
FY 20252024-12-31394.942026-03-1710-K
Q3 20252024-09-30754.852025-11-1210-Q
Q2 20252024-06-30381.092025-08-1210-Q
Q1 20252024-03-3112.292025-05-1310-Q
FY 20242023-12-3144.232025-03-1810-K
Q3 20242023-09-303.202024-11-1410-Q
Q2 20242023-06-309.612024-08-2910-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.